March 21, 2013

Schnitzler's syndrome: diagnosis, treatment, and follow-up


You have free access to this content

Schnitzler's syndrome: diagnosis, treatment, and follow-up

Abstract

Schnitzler's syndrome is characterized by recurrent urticarial rash and monoclonal gammopathy, associated with clinical and biological signs of inflammation and a long-term risk of AA amyloidosis and overt lymphoproliferation. An extensive literature review was performed, and the following questions were addressed during an expert meeting: In whom should Schnitzler's syndrome be suspected? How should the diagnosis of Schnitzler's syndrome be established? How should a patient with Schnitzler's syndrome be treated? How should a patient with Schnitzler's syndrome be followed up?. A diagnosis of Schnitzler's syndrome is considered definite in any patient with two obligate criteria: a recurrent urticarial rash and a monoclonal IgM gammopathy, and two of the following minor criteria: recurrent fever, objective signs of abnormal bone remodeling, elevated CRP level or leukocytosis, and a neutrophilic infiltrate on skin biopsy. It is considered probable, if only 1 minor criterion is present. In patients with monoclonal IgG gammopathies, diagnosis is definite if three minor criteria are present and possible if two are present. First-line treatment in patients with significant alteration of quality of life or persistent elevation of markers of inflammation should be anakinra. Follow-up should include clinical evaluation, CBC and CRP every 3 months and MGUS as usually recommended.

  1. A. Simon1, 
  2. B. Asli2, 
  3. M. Braun-Falco3, 
  4. H. De Koning4, 
  5. J.-P. Fermand2, 
  6. C. Grattan5,
  7. K. Krause6, 
  8. H. Lachmann7, 
  9. C. Lenormand8, 
  10. V. Martinez-Taboada9, 
  11. M. Maurer6, 
  12. M. Peters10, 
  13. R. Rizzi11, 
  14. F. Rongioletti12, 
  15. T. Ruzicka3, 
  16. L. Schnitzler13, 
  17. B. Schubert14,
  18. J. Sibilia15, 
  19. D. Lipsker8
Article first published online: 9 MAR 2013
DOI: 10.1111/all.12129

No comments:

Post a Comment